Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?

• Jan-Patrick Stellmann ,

  * E-mail: j.stellmann@uke.de

  ¶‡ JPS and KHS contributed equally to this work. TF and CH also contributed equally to this work.

  Affiliation Institute for Neuroimmunology and MS (inims) and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Klarissa Hanja Stürner ,

  ¶‡ JPS and KHS contributed equally to this work. TF and CH also contributed equally to this work.

  Affiliation Institute for Neuroimmunology and MS (inims) and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Kim Lea Young,

  Affiliation Institute for Neuroimmunology and MS (inims) and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Susanne Siemonsen,

  Affiliation Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯
• Tim Friede ,

  ¶‡ JPS and KHS contributed equally to this work. TF and CH also contributed equally to this work.

  Affiliation Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany

  ⨯
• Christoph Heesen

  ¶‡ JPS and KHS contributed equally to this work. TF and CH also contributed equally to this work.

  Affiliation Institute for Neuroimmunology and MS (inims) and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  ⨯